|
| | Issue Date | Title | Contributor(s) | Type | Cat. |
| 1 | 2019 | Improved Clinical and MRI Disease Activity Outcomes, Including Slowing of Brain Volume Loss, in Alemtuzumab-Treated RRMS Patients: 8-Year Follow-up of CARE-MS I (TOPAZ Study) | Pelletier, Daniel; Arnold, Douglas L.; Boyko, Alexey N.; Comi, Giancarlo; Hartung, Hans-Peter; Havrdova, Eva Kubala; Inshasi, Jihad Said; McCombe, Pamela; Nakamura, Kunio; Oreja-Guevara, Celia; Pozzilli, Carlo; Selmaj, Krzysztof W.; Scott, Thomas F.; Chung, Luke; Daizadeh, Nadia; Afsar, Salman; VAN WIJMEERSCH, Bart | Journal Contribution | M |
| 2 | 2019 | No Association Between Lymphocyte Pharmacodynamics and Disability Following Alemtuzumab Treatment in patients With Relapsing-Remitting Multiple Sclerosis | Meuth, Sven G.; Brandes, David; Carraro, Matthew; Comi, Giancarlo; Mao-Draayer, Yang; Izquierdo, Guillermo; Kim, Ho Jin; Pardo, Gabriel; Sharrack, Basil; Tornatore, Carlo; VAN WIJMEERSCH, Bart; Ziemssen, Tjalf; Jacobs, Alan; Chung, Luke; Daizadeh, Nadia; Wiendl, Heinz | Journal Contribution | M |
| 3 | 2019 | Baseline characteristics of patients enrolled in LEMQoL, a study assessing health-related quality of life in RRMS patients treated with alemtuzumab in a real-world clinical setting | VAN WIJMEERSCH, Bart; Patti, F.; Hobart, J.; Kizlaitiene, R.; Vanderdonckt, P.; Shor, S.; Andreasen, A. K.; Uitdehaag, B. M. | Journal Contribution | M |
| 4 | 2019 | Neuromyelitis Optica in Flanders: an epidemiological study | Blomme, L.; MOONS, Lynn; Noels, S.; Laureys, G.; VAN WIJMEERSCH, Bart; Crols, R.; DE KLIPPEL, Nina; Van de Velde, K.; Willekens, B. | Journal Contribution | M |
| 5 | 2019 | Alemtuzumab improves clinical and MRI outcomes, including slowing of brain volume loss, in RRMS patients over 8 years: CARE-MS I follow-up (TOPAZ Study) | Comi, G.; Arnold, D. L.; Boyko, A. N.; Hartung, H. -P.; Havrdova, E. K.; Inshasi, J. S.; McCombe, P.; Nakamura, K.; Oreja-Guevara, C.; Pelletier, D.; Pozzilli, C.; Selmaj, K. W.; Scott, T. F.; Chung, L.; Daizadeh, N.; Afsar, S.; VAN WIJMEERSCH, Bart | Journal Contribution | M |
| 6 | 2019 | Use of other disease-modifying therapies after or between alemtuzumab treatments: pooled results from the CAMMS223, and CARE-MS I and II studies over 8 years | Vermersch, P.; Baker, M.; Bass, A. D.; Berkovich, R.; Comi, G.; Eichau, S.; Graves, D.; Hunter, S. F.; Ionete, C.; Limmroth, V.; Meuth, S. G.; Naismith, R. T.; Sharrack, B.; Subei, A.; Daizadeh, N.; Choudhry, Z.; VAN WIJMEERSCH, Bart | Journal Contribution | M |
| 7 | 2019 | Alemtuzumab improves outcomes in RRMS patients who switched from SC IFNB-1a: 6-year follow-up of CARE-MS I Patients (TOPAZ Study) | Montalban, X.; Barone, D.; Broadley, S.; Dive, D.; Hupperts, R. M.; Lycke, J.; Massacesi, L.; Naismith, R. T.; Nakamura, K.; Pandey, K.; Schippling, S.; Vermersch, P.; Wiendl, H.; Chung, L.; Daizadeh, N.; Afsar, S.; VAN WIJMEERSCH, Bart | Journal Contribution | M |
| 8 | 2019 | Alemtuzumab Improves Clinical and MRI Disease Activity Outcomes, Including Slowing of Brain Volume Loss, in RRMS Patients Over 8 Years: CARE-MS I Follow-up (TOPAZ Study) | McCombe, P.; Comi, G.; Arnold, D. L.; Boyko, A. N.; Hartung, H-P; Havrdova, E. K.; Inshasi, J. S.; Nakamura, K.; Oreja-Guevara, C.; Pelletier, D.; Pozzilli, C.; Selmaj, K. W.; Scott, T. F.; Chung, L.; Daizadeh, N.; Afsar, S.; VAN WIJMEERSCH, Bart | Journal Contribution | M |
| 9 | 2019 | Ocrelizumab treatment satisfaction in patients with suboptimal response to previous disease-modifying therapies | VAN WIJMEERSCH, Bart; Buffels, R.; Clinch, S.; Kuhelj, R.; Wei, W.; Vermersch, P. | Journal Contribution | M |
| 10 | 2019 | Therapeutic lag in relapsing multiple sclerosis | ROOSEN, Inge; Frascoli, F.; Horakova, D.; Havrdova, E. K.; Trojano, M.; Izquierdo, G.; Eichau, S.; Patti, F.; Onofr, M.; Lugaresi, A.; Prat, A.; Girard, M.; Duquette, P.; Ozakbas, S.; Grammond, P.; Sola, P.; Ferraro, D.; Bergamaschi, R.; Boz, C.; Cartechini, E.; Sa, M. J.; Terzi, M.; Alroughani, R.; Grand'Maison, F.; Granella, F.; Iuliano, G.; Hupperts, R.; Lechner-Scott, J.; Spitaleri, D.; Van Pesch, V.; Soysal, A.; Prevost, J.; Aguera-Morales, E.; Olascoaga, J.; Turkoglu, R.; Sidhom, Y.; Gouider, R.; VAN WIJMEERSCH, Bart; Butzkueven, H.; Malpas, C.; Kalincik, T. | Journal Contribution | M |
| 11 | 2019 | Fluoxetine in progressive multiple sclerosis: The FLUOX-PMS trial | Cambron, Melissa; Mostert, Jop; D'Hooghe, Marie; Nagels, Guy; Willkens, Barbara; Debruyne, Jan; Algoed, Luc; Verhagen, Winn; Hupperts, Raymond; Heersema, Dorothea; De Keyser, Jacques; De Groot, Liesbeth; Foselle, Erwin; Guillaume, Daniel; Merckx, Henri; Vanopdenbosch, Ludo; Vokaer, Mathieu; DE KLIPPEL, Nina; Nuytten, Dirk; Van Remoortel, Ann; Symons, Anoek; D'haeseleer, Miguel; Bissay, Veronique; Van Merhaegen-Wieleman, Annick; Van Lint, Michel; Michiels, Veronique; Haentjens, Patrick; VAN WIJMEERSCH, Bart; Tillemans, Bart; Van Hecke, Wim; Hengstman, Gerald | Journal Contribution | A1 |
| 12 | 2019 | Comparison of the effectiveness of rituximab versus alemtuzumab and natalizumab in active relapsing-remitting MS | Kalincik, T.; Malpas, C. B.; ROOSEN, Inge; Patti, F.; Butzkueven, H.; Alroughani, R.; Izquierdo, G.; Eichau, S.; Onofrj, M.; Lugaresi, A.; Hupperts, R.; Lechner-Scott, J.; Sola, P.; Ferraro, D.; Grammond, P.; Csepany, T.; Grand'Maison, F.; Yamout, B.; Prat, A.; Girard, M.; Duquette, P.; VAN WIJMEERSCH, Bart; Granella, F.; Sa, M. J.; Bergamaschi, R.; Slee, M.; Boz, C.; Ozakbas, S.; Terzi, M.; Prevost, J.; Solaro, C.; Macdonell, R.; Cartechini, E.; Coles, A.; Havrdova, E. K.; Horakova, D. | Journal Contribution | M |
| 13 | 2019 | Efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis with a suboptimal response to previous disease-modifying therapies (1-year interim results) | Vermersch, P.; Eralinna, J. -P.; Nicholas, R.; Oreja-Guevara, C.; Siva, A.; VAN WIJMEERSCH, Bart; Wiendl, H.; Buffels, R.; Kuhelj, R.; Wei, W.; Comi, G. | Journal Contribution | M |
| 14 | 2019 | Introducing Machine Learning for full MS patient trajectories improves predictions for disability score progression | DE BROUWER, Edward; PEETERS, Liesbet; BECKER, Thijs; Altintas, A.; Soysal, A.; VAN WIJMEERSCH, Bart; Boz, C.; Oreja-Guevara, C.; Gobbi, C.; Solaro, C.; Ramo, C.; Spitaleri, D. L.; Maimone, D.; Aguera-Morales, E.; Cartechini, E.; Butler, E.; Havrdova, E.; Patti, F.; Granella, F.; Grand'Maison, F.; Moore, F.; Verheul, F.; Luliano, G.; Butzkueven, H.; Lechner-Scott, J.; Kuhle, J.; Sanchez Menoyo, J. L.; Rojas, J. I.; Prevost, J.; Onofrj, M.; Rio, M. E.; Sa, M. J.; Saladino, M. L.; Slee, M.; Barnett, M.; Terzi, M.; Deri, N.; McCombe, P.; Sola, P.; Duquette, P.; Grammond, P.; Ampapa, R.; Alroughani, R.; Hupperts, R.; Turkoglu, R.; Gouider, R.; Fernandez Bolanos, R.; Bergamaschi, R.; Kalincik, T.; Moreau, Y. | Journal Contribution | M |
| 15 | 2019 | Best Practices for Long-Term Monitoring and Follow-Up of Alemtuzumab-Treated MS Patients in Real-World Clinical Settings | Barclay, Krista; Carruthers, Robert; Traboulsee, Anthony; Bass, Ann D.; LaGanke, Christopher; Bertolotto, Antonio; Boster, Aaron; Celius, Elisabeth G.; de Seze, Jerome; Dela Cruz, Dionisio; Habek, Mario; Lee, Jong-Mi; Limmroth, Volker; Meuth, Sven G.; Oreja-Guevara, Celia; Pagnotta, Patricia; Vos, Cindy; Ziemssen, Tjalf; Baker, Darren P.; VAN WIJMEERSCH, Bart | Journal Contribution | A1 |
| 16 | 2019 | Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis | Kalincik, Tomas; Havrdova, Eva Kubala; Horakova, Dana; Izquierdo, Guillermo; Prat, Alexandre; Girard, Marc; Duquette, Pierre; Grammond, Pierre; Onofrj, Marco; Lugaresi, Alessandra; Ozakbas, Serkan; Kappos, Ludwig; Kuhle, Jens; Terzi, Murat; Lechner-Scott, Jeannette; Boz, Cavit; Grand'Maison, Francois; Prevost, Julie; Sola, Patrizia; Ferraro, Diana; Granella, Franco; Trojano, Maria; Bergamaschi, Roberto; Pucci, Eugenio; Turkoglu, Recai; McCombe, Pamela A.; Van Pesch, Vincent; VAN WIJMEERSCH, Bart; Solaro, Claudio; Ramo-Tello, Cristina; Slee, Mark; Alroughani, Raed; Yamout, Bassem; Shaygannejad, Vahid; Spitaleri, Daniele; Luis Sanchez-Menoyo, Jose; Ampapa, Radek; Hodgkinson, Suzanne; Karabudak, Rana; Butler, Ernest; Vucic, Steve; Jokubaitis, Vilija; Spelman, Tim; Butzkueven, Helmut | Journal Contribution | A1 |
| 17 | 2019 | Predicting long-term sustained disability progression in multiple sclerosis | SHARMIN, Sohely; Malpas, C.; Horakova, D.; Havrdova, E. K.; Izquierdo, G.; Eichau, S.; Trojano, M.; Prat, A.; Girard, M.; Duquette, P.; Onofrj, M.; Lugaresi, A.; Grand'Maison, F.; Grammond, P.; Sola, P.; Ferraro, D.; Terzi, M.; Hupperts, R.; Alroughani, R.; Boz, C.; Shaygannejad, V.; Van Pesch, V.; Cartechini, E.; Kappos, L.; Lechner-Scott, J.; Bergamaschi, R.; Turkoglu, R.; Solaro, C.; Ramo-Tello, C.; Iuliano, G.; Granella, F.; VAN WIJMEERSCH, Bart; Spitaleri, D.; Bolanos, R. F.; Slee, M.; McCombe, P.; Prevost, J.; Ampapa, R.; Ozakbas, S.; Sanchez-Menoyo, J. L.; Soysal, A.; Vucic, S.; Petersen, T.; Verheul, F.; Butler, E.; Hodgkinson, S.; Sidhom, Y.; Gouider, R.; Butzkueven, H.; Kalincik, T. | Journal Contribution | M |
| 18 | 2019 | Comparative effectiveness of natalizumab and fingolimod in different subgroups of patients with relapsing-remitting multiple sclerosis | SHARMIN, Sohely; Lefort, M.; Andersen, J.; Horakova, D.; Havrdova, E. K.; Alroughani, R.; Izquierdo, G.; Eichau, S.; Ozakbas, S.; Butzkueven, H.; Patti, F.; Onofrj, M.; Lugaresi, A.; Terzi, M.; Grammond, P.; Grand'Maison, F.; Yamout, B.; Prat, A.; Girard, M.; Duquette, P.; Boz, C.; Trojano, M.; McCombe, P.; Slee, M.; Lechner-Scott, J.; Turkoglu, R.; Sola, P.; Ferraro, D.; Granella, F.; Shaygannejad, V.; Prevost, J.; Skibina, O.; Solaro, C.; Karabudak, R.; VAN WIJMEERSCH, Bart; Csepany, T.; Spitaleri, D.; Vucic, S.; Leray, E.; Sorensen, P. S.; Sellebjerg, F.; Magyari, M.; Vukusic, S.; Kalincik, T. | Journal Contribution | M |
| 19 | 2019 | Phenotypic and Ig Repertoire Analyses Indicate a Common Origin of IgD-CD27- Double Negative B Cells in Healthy Individuals and Multiple Sclerosis Patients | FRAUSSEN, Judith; Marquez, Susanna; Takata, Kazushiro; BECKERS, Lien; MONTES DIAZ, Gwendoline; Zografou, Chrysoula; VAN WIJMEERSCH, Bart; Villar, Luisa M.; O'Connor, Kevin C.; Kleinstein, Steven H.; SOMERS, Veerle | Journal Contribution | A1 |
| 20 | 2019 | IgD(-)CD27(-) double negative B cells of multiple sclerosis patients have a pro-inflammatory migratory phenotype and function | BECKERS, Lien; Diaz, G. Montes; Villar, L. M.; VAN WIJMEERSCH, Bart; SOMERS, Veerle; FRAUSSEN, Judith | Journal Contribution | M |
Loading...
5
0
5
0
false